John at 19:45, 4 July 2023

2023-07-04T19:45:52Z

← Older revision		Revision as of 21:45, 4 July 2023
Line 62:		Line 62:
	\|-		\|-
	!colspan="8"\|'''Expression in mature B cell neoplasms'''		!colspan="8"\|'''Expression in mature B cell neoplasms'''
	\|-		\|- <span style="font-size:70%">
	! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL		! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL \|\| LPL !! PCL
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%

John at 11:12, 3 July 2023

2023-07-03T11:12:14Z

← Older revision		Revision as of 13:12, 3 July 2023
Line 41:		Line 41:
	{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"		{\| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
	\|-		\|-
	!colspan="8"\|~~<span style="font-size:100%">~~'''Expression in primitive cell types'''</font>		!colspan="8"\|'''Expression in primitive cell types'''</font>
	\|-		\|- <span style="font-size:70%">
	! AML !! CMML !! B ALL !! ~~Burkitt~~ \|\| T ALL !! ETP ALL ~~<'''[[ETP ALL\|I]]'''>~~ !! ~~MPAL <'''[[~~MPAL~~\|I]]'''>~~ \|\| ~~Hgns~~ <~~'''[[Hgns\|I]]'''~~>		!AML!!CMML !!B ALL !!BL \|\|T ALL !!ETP ALL !!MPAL \|\|Hgn</span>
	\|-		\|-<span style="font-size:70%">
	\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%
	\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%		\|style="width: 12.5%; background: #E6FAFF; color:wblack"\|<5%

John at 09:22, 12 June 2023

2023-06-12T09:22:32Z

← Older revision		Revision as of 11:22, 12 June 2023
Line 86:		Line 86:
	! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL		! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
	\|-		\|-
	\|style="width: 14.25%; background: #006699; color:~~black~~"\|40-80%		\|style="width: 14.25%; background: #006699; color:white"\|40-80%
	\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%
	\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%		\|style="width: 14.25%; background: #E6FAFF; color:black"\|<5%

John: Created page with "
:'''Summary''' :The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological identification of a range of myeloid and T-cell disorders.
'''Normal expression and function''' CD1..."

2023-06-12T09:21:39Z

Created page with " <div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;"> :'''Summary''' :The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological identification of a range of myeloid and T-cell disorders. </div> '''Normal expression and function''' CD1..."

New page

<div style="background-color: #E0EEEE; {{round corners}} padding: 2em 2em; margin-right: 5px;">

:'''Summary'''

:The principle use of CD103 is to identify hairy cell leukaemia (HCL) and distinguish it from related diorders. CD103 also has a wider range of applications in the histopathological identification of a range of myeloid and T-cell disorders.

</div>

'''Normal expression and function'''

CD103 belongs to the integrin family of adhesion proteins, and directs the adhesion of a subset of T cells within intestinal endothelium and other mucosal sites (binding to E-cadherin). In normal tissues CD103 is found mainly on normal intraepithelial T cells (both alpha-beta or gamma-delta type) and is also expressed by some peripheral regulatory T cells (TRegs) as well as specialised dendritic cells in the gut mucosa and mesenteric lymph nodes.

'''Diagnostic role'''

*CD103 is consistently expressed on hairy cell leukemia (HCL) with relatively high (although not complete) specificity.
*CD103 is not generally found on other B-cell lymphomas

'''Other useful information'''

In histopathology CD103 is used to identify enteropathy-associated T cell lymphoma, and in lung CD103 has been used in bronchoalveolar lavage to diagnose pulmonary sarcoidosis.

----

'''''SUMMARY TABLES'''''

'''Note''' The colour and % refer to the proportion of cases expressing the marker. Additional comments on strength, or site of expression (if relevant) are given below the table. For full details of key click [[Key to marker expression table|here]]. For further information about a particular disease state click <'''I'''> adjacent to the condition name

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in primitive cell types'''
|-
! AML !! CMML !! B ALL !! Burkitt || T ALL !! ETP ALL <'''[[ETP ALL|I]]'''> !! MPAL <'''[[MPAL|I]]'''> || Hgns <'''[[Hgns|I]]'''>
|-
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|-
|}

'''Notes:''' ''**''While a good marker of B lineage it may not be expressed in more primitive phenotype ALL, there is also a recognised abberrant expression in AML (particularly cases with t)8;21) 

{| class=wikitable style="text-align: center; font-size:80%; width: 100%; height 20px;"
|-
!colspan="8"|'''Expression in mature B cell neoplasms'''
|-
! CLL !! MCL !!FL!! MZL !! HCL !! DLBCL || LPL !! PCL
|-
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #004466; color:white"|80-100%**
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|style="width: 12.5%; background: #E6FAFF; color:wblack"|<5%
|-
|}

'''Notes:''' *typically expressed in HCL where it will be detected in most cases; generally absent in other LPD although rarely expression is detected so the overall pattern is important 

{| class=wikitable style="text-align: center; font-size:80%; width: 62.4%; height 40px;"
|-
!colspan="7"|'''Expression in mature T cell neoplasms*'''
|-
! ATLL !! CTCL/Sezary !! T-PLL !! T-LGL !! NK-LGL
|-
|style="width: 14.25%; background: #006699; color:black"|40-80%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|style="width: 14.25%; background: #E6FAFF; color:black"|<5%
|-
|}

'''Notes:''' Sporadic expression is recognised in many T-cell disorders at around 5% of cases, expression is more frequent in ATLL where just over 40% of cases may express CD103 

----

CD103 - Revision history

John at 19:45, 4 July 2023

John at 11:12, 3 July 2023

John at 09:22, 12 June 2023